Overview Fundamentals API Earnings EOD API Sample Code Pricing

NewAmsterdam Pharma Company N.V. Warrant (NAMSW NASDAQ) stock market data APIs

$8.35 -0.01(-0.1%) as of July 18, 2024
Price chart is built with Anychart

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NewAmsterdam Pharma Company N.V. Warrant Financial Data Overview

6 862 K
Our easy-to-use no-coding solutions help you get the data effortlessly:

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'NAMSW',
Type: 'Common Stock',
Name: 'NewAmsterdam Pharma Company N.V. Warrant',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG01BNP2MK0',
CIK: '1936258',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2022-11-23',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Warrant',
IsDelisted: false,

NewAmsterdam Pharma Company N.V. Warrant Fundamental Data is available in our Financial Data APIs

  • Net Revenue 6 862 K
  • EBITDA -198 540 992
  • Earnings Per Share
  • Income Statements
  • Balance Sheets
  • Cash flows
Get sample
of Fundamental API Data

Get NewAmsterdam Pharma Company N.V. Warrant Earnings via APIs

  • Latest Release NaN
  • EPS/Forecast NaN

Get NewAmsterdam Pharma Company N.V. Warrant End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?